Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Recurrence × Dosage Forms × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Prostatic Neoplasms 1 Neurofibromatosis 1 1 Multiple Myeloma 1 Leukemia, Myeloid, Acute 1 Advanced Solid Tumors 1

Interventions

Dexamethasone 42 Cyclophosphamide 37 fludarabine phosphate 27 Cytarabine 26 Rituximab 24 Methotrexate 21 Lenalidomide 21 Bortezomib 21 Calcium Dobesilate 20 fludarabine 19 Peripheral Blood Stem Cell Transplantation 19 Whole-Body Irradiation 16 Mycophenolic Acid 16 Gemcitabine 15 Etoposide 15 pembrolizumab 14 Melphalan 14 pomalidomide 13 Vincristine 13 Filgrastim 13 Busulfan 13 Tacrolimus 12 Cyclosporine 12 Carboplatin 12 Paclitaxel 11 carfilzomib 10 durvalumab 9 Doxorubicin 9 Cetuximab 9 Brentuximab Vedotin 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡